NACLC 2023
Advertisement
Chemotherapy-induced myelosuppression among patients with extensive-stage SCLC is poorly understood.
The VISION study that evaluated pre/post-tepotinib treatment in advanced/metastatic METex14 skipping NSCLC.
The DeLLphi-301 study evaluated patients with advanced SCLC.
Results of a study that evaluated the impact of comprehensive versus limited NGS for advanced NSCLC.
A study evaluated second-line treatment patterns and clinical outcomes of IO in NSCLC.
Patients with metastatic NSCLC who receive first-line anti-PD-L1-based IO may achieve durable disease control.
Lurbinectedin monotherapy is currently being studied in Jazz EMERGE 402 study in patients with metastatic SCLC.
Black and/or socioeconomically disadvantaged patients with advanced NSCLC have higher mortality rates.
Results of a lung screening program found a significantly higher lung cancer prevalence in veterans.
A greater understanding of patients with HER2-mutated NSCLC is critical for developing therapies.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
Connect
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.